PD‑L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study-Reference-Cited by-同舟云学术

PD‑L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study

Published:2021-05-24 Issue:1 Volume:22 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Cameselle‑García Soledad¹,Abdulkader‑Sande Sámer²,Sánchez‑Ares María²,Rodríguez‑carnero Gemma³,Garcia‑Gómez Jesús¹,Gude‑Sampedro Francisco⁴,Abdulkader‑Nallib Ihab²,Cameselle‑teijeiro José²

Affiliation:

1. Department of Medical Oncology, University Hospital Complex of Ourense, Galician Healthcare Service, 32005 Ourense, Spain

2. Department of Pathology, Clinical University Hospital of Santiago de Compostela, Health Research Institute of Santiago de Compostela, Galician Healthcare Service, 15706 Santiago de Compostela, Spain

3. Department of Endocrinology, Clinical University Hospital of Santiago de Compostela, Health Research Institute of Santiago de Compostela, Galician Healthcare Service, 15706 Santiago de Compostela, Spain

4. Department of Epidemiology, Clinical University Hospital of Santiago de Compostela, Health Research Institute of Santiago de Compostela, Galician Healthcare Service, 15706 Santiago de Compostela, Spain

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of CTLA-4 and PD-L1 Expression in Thyroid Carcinoma and Its Prognostic Significance;Cureus;2024-08-16

2. Immuntherapie von Schilddrüsenkarzinomen;TumorDiagnostik & Therapie;2024-08

3. PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma;American Journal of Surgical Pathology;2024-07-15

4. Nearly Half of Patients with Anaplastic Thyroid Cancer May Be Amenable to Immunotherapy;Biomedicines;2024-06-12

5. Immuntherapie von Schilddrüsenkarzinomen;Angewandte Nuklearmedizin;2024-03